0001415889-24-004625.txt : 20240221
0001415889-24-004625.hdr.sgml : 20240221
20240221163147
ACCESSION NUMBER: 0001415889-24-004625
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240216
FILED AS OF DATE: 20240221
DATE AS OF CHANGE: 20240221
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Yednock Ted
CENTRAL INDEX KEY: 0001818525
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39402
FILM NUMBER: 24660149
MAIL ADDRESS:
STREET 1: C/O ANNEXON, INC.
STREET 2: 180 KIMBALL WAY, SUITE 200
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Annexon, Inc.
CENTRAL INDEX KEY: 0001528115
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 275414423
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1400 SIERRA POINT PARKWAY
STREET 2: BLDG C, SUITE 200
CITY: BRISBANE
STATE: CA
ZIP: 94005
BUSINESS PHONE: (650)-822-5500
MAIL ADDRESS:
STREET 1: 1400 SIERRA POINT PARKWAY
STREET 2: BLDG C, SUITE 200
CITY: BRISBANE
STATE: CA
ZIP: 94005
4
1
form4-02212024_040217.xml
X0508
4
2024-02-16
0001528115
Annexon, Inc.
ANNX
0001818525
Yednock Ted
C/O ANNEXON, INC
1400 SIERRA POINT PKWY, BLDG C, STE 200
BRISBANE
CA
94005
false
true
false
false
EVP & CHIEF INNOVATION OFFICER
0
Common Stock
2024-02-16
4
A
0
39000
0
A
75075
D
Common Stock
2024-02-20
4
S
0
2604
5.51
D
72471
D
Common Stock
21000
I
By Spouse
Stock Option (Right to Buy)
5.13
2024-02-16
4
A
0
160000
0
A
2034-02-16
Common Stock
160000
160000
D
Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on February 16 of each year, with the first 1/3rd vesting on February 16, 2025.
The shares were sold to cover tax withholding obligations in connection with the vesting of RSUs.
This transaction was executed in multiple trades in prices ranging from $5.34 to $5.58, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
1/48th of the shares subject to the option vest on each monthly anniversary measured from February 16, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
/s/ Jennifer Lew, Attorney-in-Fact
2024-02-21